Physical Activity Might Not Reduce Schizophrenia Risk
WEDNESDAY, Dec. 16, 2020 -- Physical activity (PA) might not protect against schizophrenia risk, according to a research letter published online Dec. 9 in JAMA Psychiatry.
Sergi Papiol, Ph.D., from the University Hospital in Munich, Germany, and colleagues examined the association between PA and schizophrenia risk using data from the U.K. Biobank.
The researchers observed no association between PA and schizophrenia risk in any analyses. There was evidence of an association between self-reported moderate/vigorous PA and increased schizophrenia risk in a univariate analysis with and without correction for body mass index (BMI). A trend for overall activity was noted in a univariate analysis, but the association was no longer significant after BMI correction. It was not likely that horizontal pleiotropy, heterogeneity, or individual single-nucleotide polymorphism effects would confound the results obtained for moderate/vigorous PA.
"Moderate/vigorous self-reported PA seems to increase schizophrenia risk, results that are difficult to align with current evidence," the authors write.
Two authors disclosed financial ties to the pharmaceutical industry.
© 2021 HealthDay. All rights reserved.
Posted: December 2020
Read this next
WEDNESDAY, Dec. 16, 2020 -- Many health care facilities still have crisis standards of care for use of personal protective equipment (PPE), according to the results of a survey...
MONDAY, Dec. 14, 2020 -- Levels of social cognitive impairment are similar in individuals with schizophrenia spectrum disorders (SSDs) and autism spectrum disorder (ASD),...
THURSDAY, April 16, 2020 -- For patients with an acute exacerbation of schizophrenia, SEP-363856, a non-D2-receptor-binding drug that has agonist activity at trace...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.